Navigation Links
Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine
Date:11/1/2010

will receive an injection of either a placebo or the H5N1 vaccine at varying doses to determine the optimal dose. In the second part of the study, healthy adults will receive an injection of either a placebo or the H5N1 vaccine at the optimal dose. Interim-results of this study are expected in less than three months.

"The initiation of our Phase II clinical trial is an important step in the development of our plant-based VLP vaccines, which we believe are highly effective, cross-protective, less expensive and faster to produce than current influenza vaccines. It also demonstrates our ability to advance candidates through clinical development," said Andy Sheldon, President and CEO of Medicago. "Our platform is very versatile and to date, we have been able to produce a broad array of other proteins with potential use in the life science industry. This clinical trial therefore provides additional validation for our rapid and cost-effective technology platform offering." About Medicago Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This news release includes certain forward-loo
'/>"/>

SOURCE Medicago Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medicago initiates work on Swine Flu strain
2. Medicago succesfully expresses VLP antigen for A H1N1 strain
3. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
4. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
5. Medicago begins human clinical testing with its avian flu pandemic vaccine
6. Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy
7. Medicago to present at the U.S. Department of Health and Human Services Global Health Security Initiative Workshop
8. Medicago reports positive Phase I results for its avian flu pandemic vaccine
9. Medicago named in Presidential report on meeting the challenges of pandemic influenza
10. Medicago discovers breakthrough method of preparing plant derived recombinant proteins and VLPs and files two PCT patent applications
11. Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Jersey (PRWEB) September 30, 2014 ... has been chosen by the Parenteral Drug Association ... 18 and 19, 2014) on container closure integrity testing. ... closure integrity test methods and philosophies detailed in the ... Integrity Evaluation. The course will span container ...
(Date:9/29/2014)... start of the military conflicts in Iraq and Afghanistan, ... States with traumatic brain injury caused by exposure to ... explosive devices, or IEDs. Symptoms of traumatic brain injury ... and nausea, to more severe impairments in memory and ... Defense has recognized the critical importance and complexity of ...
(Date:9/29/2014)... Present-day lithium batteries are efficient but involve a ... from alfalfa (lucerne seed) and pine resin and ... come up with a highly interesting alternative. Their ... journal ChemSusChem . , ,We think our ... energy-efficient solutions for the batteries of the future, ...
(Date:9/29/2014)... Mass. , Sept. 29, 2014  Atlas Venture, ... life sciences and technology innovation, today announced that ... Epizyme (NASDAQ: EPZM ), is joining the ... October 1, 2014. At Atlas, Rhodes will ... groundbreaking companies. He brings an accomplished record in company ...
Breaking Biology Technology:Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4Smart, eco-friendly new battery to solve problems 2Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team 2
... Software, a leading provider of image data management tools for ... Open Microscopy Environment Consortium, is proud that its founder Professor ... this year,s BBSRC Innovator of the Year. The BBSRC is ... in the non-clinical life sciences, and along with the Wellcome ...
... the best education and to absorb what they are ... the journal Academic Medicine * connects research on how ... real world education, particularly the education of doctors. "Repetition, ... knowing what is happening in the brain will enhance teaching ...
... surgeon Dr. Lewis Groden presented results from a ... and Refractive Surgery (ASCRS) Symposium revealing that LASIK procedures ... and very high patient satisfaction rates. Each ... vision center currently offers patients a choice of multiple ...
Cached Biology Technology:Glencoe Software and Open Microscopy Environment Founder Awarded the BBSRC Innovator of the Year 2011 2Brain scientists offer medical educators tips on the neurobiology of learning 2Brain scientists offer medical educators tips on the neurobiology of learning 3Brain scientists offer medical educators tips on the neurobiology of learning 4Brain scientists offer medical educators tips on the neurobiology of learning 5LasikPlus® Research Reveals Excellent Results From Modern LASIK 2
(Date:9/29/2014)... Joint Genome Institute (DOE JGI), a DOE Office ... new projects have been selected for the 2015 ... to Caribbean waters, and from plant root micro-ecosystems, ... forested watersheds, the CSP 2015 projects portfolio highlights ... extracted. , "These projects catalyze JGI,s strategic ...
(Date:9/29/2014)... can DNA from the skeleton of a man who lived ... us about ourselves as humans? A great deal when his ... in genetic terms found to-date in a region where ... ago. , The man,s maternal DNA, or ,mitochondrial DNA, ... and evolution. Mitochondrial DNA provided the first evidence that we ...
(Date:9/29/2014)... CHAMPAIGN, Ill. Scientists have discovered a previously ... divide, grow and, in the case of estrogen-positive ... the work reveals new targets for breast cancer ... need the most aggressive treatment. , The University ... journal Oncogene . , Estrogen pre-activates the ...
Breaking Biology News(10 mins):2015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9Ancient human genome from southern Africa throws light on our origins 2Ancient human genome from southern Africa throws light on our origins 3Scientists discover a new role for estrogen in the pathology of breast cancer 2
... researchers have found that the naturally occurring marine toxin ... in rats exposed to the chemical before birth. Humans ... after eating contaminated shellfish. , The researchers saw ... exposure to domoic acid levels below those generally deemed ...
... (Nasdaq: SLXA) today announced that its researchers in collaboration ... Delaware reported the most comprehensive analysis to date of ... "Elucidation of the Small RNA Component of the Transcriptome," ... the peer-reviewed journal Science. Solexa's assay can be used ...
... Medicine uses PET, radiotracer to track enzyme in smokers, ... in the lungs, possibly contributing to some of smoking's ... the September issue of the Journal of Nuclear Medicine. ... enzyme, also shows that smokers had a lower concentration ...
Cached Biology News:Prenatal exposure to marine toxin causes lasting damage 2Prenatal exposure to marine toxin causes lasting damage 3Solexa and collaborating scientists illuminate the small RNA component of the transcriptome 2Smoking damages key regulatory enzyme in the lung 2Smoking damages key regulatory enzyme in the lung 3
Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
...
Form: Concentrated Applications: ELISA...
Form: Ready to use Applications: ELISA...
Biology Products: